Next Article in Journal
Impact of Coronavirus Disease 2019 on Out-of-Hospital Cardiac Arrest Survival Rate: A Systematic Review with Meta-Analysis
Previous Article in Journal
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
Article

Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot

1
Department of Surgical Infections, University Medical Center Ljubljana, Zaloska Cesta 2, 1000 Ljubljana, Slovenia
2
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska Cesta 2, 1000 Ljubljana, Slovenia
3
Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
Academic Editor: José Luis Lázaro-Martínez
J. Clin. Med. 2021, 10(6), 1208; https://doi.org/10.3390/jcm10061208
Received: 13 February 2021 / Revised: 7 March 2021 / Accepted: 12 March 2021 / Published: 15 March 2021
(This article belongs to the Section Orthopedics)
Biomechanically, the great toe with its metatarsophalangeal (MTP) joint plays a key role in standing and walking, making the first MTP joint one of the main predilection sites for ulcer formation, and consequently for bone and joint infection and even amputation. If conservative treatment fails, the main goal of surgery is to remove all infected tissue and preserve the first ray. To improve surgical outcomes, development of new biomaterials like Bioactive Glass S53P4 has begun. Bioactive Glass is useful because of its antibacterial properties; furthermore, its osteostimulative and osteoconductive qualities make the bone substitute particularly suitable as a bone defect filler for the treatment of osteomyelitis. The aim of our retrospective observational study was to compare the outcomes following ulcerectomy with segmental resection of the infected joint and bone and temporary stabilization with an external fixator, both with and without added Bioactive Glass. A comparison of added Bioactive Glass with the traditional surgical treatment in septic osteoarthritis of the first MTP joint showed Bioactive Glass to be effective. During a one-year follow-up, patients with Bioactive Glass required no additional antibiotic therapy or surgical intervention. Bioactive Glass, when applied to the diabetic foot, showed itself to be a safe bone substitute biomaterial. View Full-Text
Keywords: septic osteoarthritis; diabetic foot; bioactive glass; foot ulcer; segmental resection of the first MTP joint; diabetic foot osteomyelitis septic osteoarthritis; diabetic foot; bioactive glass; foot ulcer; segmental resection of the first MTP joint; diabetic foot osteomyelitis
Show Figures

Figure 1

MDPI and ACS Style

Kastrin, M.; Urbančič Rovan, V.; Frangež, I. Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot. J. Clin. Med. 2021, 10, 1208. https://doi.org/10.3390/jcm10061208

AMA Style

Kastrin M, Urbančič Rovan V, Frangež I. Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot. Journal of Clinical Medicine. 2021; 10(6):1208. https://doi.org/10.3390/jcm10061208

Chicago/Turabian Style

Kastrin, Matevž, Vilma Urbančič Rovan, and Igor Frangež. 2021. "Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot" Journal of Clinical Medicine 10, no. 6: 1208. https://doi.org/10.3390/jcm10061208

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop